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INTRODUCTION
Oral high-dose busulfan is used widely as a myeloabla-
tive and antileukemic treatment in preparation for bone
m a rrow or peripheral blood stem cell transplantation
(hematopoietic stem cell transplantation [HSCT]) [1–3]. In
randomized studies comparing busulfan with irr a d i a t i o n -
containing regimens, comparable overall efficacy was shown
in all but one study in patients with acute myelogenous
leukemia [4]. The use of busulfan is not without problems,
however [5–10]. Highly variable busulfan concentration
profiles have been observed, presumably caused by variable
gastrointestinal absorption [11,12]. The incidence of hepatic
veno-occlusive disease (VOD), an often life-threatening reg-
i m e n - related toxicity, appears to increase with exposure to
higher busulfan levels [5,9,10,13,14]. At the same time,
reduced busulfan concentrations might be associated with
increased risks of graft rejection and recurrence of leukemia
[10]. For this reason, studies performed with exposure-guid-
ed dose adjustment employing area under the curve (AUC)
analysis have aimed at achieving safer or more eff i c a c i o u s
plasma busulfan concentrations [15–18]. One strategy that
may circumvent pharmacokinetic problems related to varia-
tions in bioavailability is the use of an intravenous formula-
tion of busulfan.
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ABSTRACT
We have previously described pharmacokinetic studies with a dimethylsulfoxide-based intravenous busulfan pre p a-
ration in a canine model and in pre l i m i n a ry clinical trials. Using the same intravenous busulfan preparation, we car-
ried out a dose escalation study to determine a marrow-ablative dose and to test the ability of autologous marrow to
reconstitute hematopoiesis in dogs so treated. Busulfan was given intravenously at doses of 3.75 to 40 mg/kg. Mar-
row ablation was achieved at 20 mg/kg given either as a single dose or in four daily increments of 5 mg/kg each.
T h e re was a relative sparing of lymphocytes. A busulfan dose of 40 mg/kg resulted in severe central nervous system
t o x i c i t y. Otherwise, nonhematopoietic toxicity was minimal and restricted to mild hepatic abnormalities. Four dogs
w e re given busulfan at 20 mg/kg followed 30 hours later by infusion of autologous marro w, and all showed pro m p t
and complete hematopoietic reconstitution. The area under the curve (AUC) determined by busulfan concentration
in plasma over time was dose dependent, ranging from 12 to 100 mg · h/mL for busulfan doses of 3.75–20 mg/kg.
T h e re was a suggestion that the plasma half-life increased at the highest busulfan doses used. Intravenous adminis-
tration of busulfan circumvented diff e rences in bioavailability; nevertheless, considerable variations in the pharm a-
cokinetic parameters were observed between individual animals. Thus, intravenous busulfan can be given safely and
is effective in ablating hematopoiesis. However, factors other than absorption influence the AUC, and individualiza-
tion of dosing may be re q u i red even with intravenous administration of the dru g .
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We previously re p o rted on the development of such a
p reparation and showed in a canine model that single
intravenous doses of 1 mg/kg busulfan resulted in peak
plasma levels of 730–1000 ng/mL and AUC values of
75–146 ng · h/kg · mL [19]. The same preparation has also
been tested in a clinical pilot study [20]. Diff e rent intra-
venous preparations of busulfan—using, for example, solu-
tions of DMSO, ethanol and polyethylene glycol (PEG) [21],
or dimethylacetamide and PEG [22,23]—have been tested by
other investigators. However, no systematic dose-re s p o n s e
study of intravenous busulfan in re g a rd to myelosuppre s s i o n
has been presented. Here we carried out a dose escalation
study in dogs to determine a myeloablative dose of the intra-
venous busulfan preparation and the ability of autologous
m a rrow to reconstitute hematopoiesis in dogs so tre a t e d .
MATERIALS AND METHODS
D og s
Sixteen beagles, 8 to 20 months old and weighing
7.8–20 kg (median 11), were housed and provided with c o m-
m e rcial chow and drinking water ad libitum as d e s c r i b e d
[24]. Kennel facilities and animal care were in accord a n c e
with the guidelines stated by the National Academy of Sci-
ences. The experimental protocol was approved by the
Institutional Animal Care and Users Committee of the Fred
Hutchinson Cancer Research Center.
For 12 hours before each experiment, dogs received no
food but had free access to drinking water. All dogs had
peripheral blood sampled for busulfan pharm a c o k i n e t i c
analysis as described below. Autologous marrow transplants
were carried out as described below. Busulfan was adminis-
tered intravenously at total doses of 3.75, 7.5, 10, 15, 17.5,
20, or 40 mg/kg (Table 1). In 15 dogs, the dose was given as
a single injection; one dog (D959) received the total dose of
20 mg/kg in four increments (5 mg/kg/day for four consecu-
tive days).
Drug pr e p a r a t i o n
The intravenous formulation was pre p a red immediately
b e f o re administration as described [19,20,25], and no PEG
was added. Briefly, busulfan powder (Aldrich Chemical,
Steinheim, Germany) was dissolved in 1 mL dimethylsulfox-
ide (DMSO), the amount re q u i red for treatment was fil t e re d
(0.2 mm PTFE filter; Lida Manufacturing, Kenosha, WI) into
50 mL 0.9% sodium chloride, the concentration was verifie d ,
and the solution was administered over 2 minutes via an
intravenous cannula. The measurements of busulfan concen-
tration in aliquots showed no loss during the pre p a r a t i o n
steps. Degradation in the solution if kept at 20°C occurred at
a rate of 5% per hour (determined over 18–24 hours).
Blood samples
Blood samples were obtained before and 0.25, 0.5, 0.75,
1, 1.5, 2, 3, 4, 5, 6, 24, and 48 hours after dosing [19]. In the
single dog (D959) given 5 mg/kg for four doses, blood was
sampled only for 24 hours, that is, until administration of
the second busulfan dose. The dog (E153) given 40 mg/kg
intravenously as a single dose developed a generalized con-
vulsion upon completion of the injection [7], had a respira-
tory arrest, and died. Thus, no postinjection blood samples
w e re available. Blood samples were immediately placed on
ice and centrifuged at 4000g at 4°C. Plasma was separated
and stored at –20°C until analysis. 
A n a ly s i s
Busulfan in plasma was assayed using a pre v i o u s l y
described high-perf o rmance l iquid chro m a t o g r a p h y
(HPLC) method with minor modifications [25]. In brief,
solid-phase extraction on Bond Elut C8 cartridges was used
for sample cleanup. In a precolumn derivatization, the
extracted busulfan was converted into 1,4-diiodobutane.
The separation of 1,4-diidobutane was achieved with an iso-
cratic HPLC system using a guard column of 5 mm LiChrosorb
CN (E. Merck, Darmstadt, Germany) and a Gromsil 100-
CNN analytical column (M. Grom, Herrenberg, Germany).
The solvent system was water-acetonitrile (78:22, vol/vol) at
a flow rate of 1 mL/min. A postcolumn photochemical
derivatization with a Teflon reactor (inner diameter 0.8 mm;
length 6 m; MSD Metron GmbH, Aschheim, Germany, and
Gynkotek, Germering, Germany) enabled the detection of
the busulfan derivative at 226 nm with a retention time of
16.5 minutes. This method has a high selectivity. The coef-
ficient of variation at a concentration of 250 ng/mL was
2.7%, and the detection limit for busulfan in plasma was
20 ng/mL. Pharmacokinetic parameters were determined by
use of the TOPFIT program, and AUC was calculated by
use of the trapezoidal rule.
Assessment of my e l o a bl a t i o n
Peripheral blood cell counts were obtained before and at
daily intervals after completion of busulfan administration.
Bone marrow cellularity was determined at autopsy. Largely
based on earlier studies with dimethylbusulfan [26] and
more recent work using various conditioning regimens [24],
a decline in neutrophils to ,10/mL combined with a platelet
Table 1. 
Pharmacokinetic parameters in dogs given intravenous busulfan
Body Dose AUC Clearance
Dog weight (kg) (mg/kg) t 1/2 (h) ( mg · h/mL) (mL/h)
E180 10.4 3.75 1.54 19 191.3
E959* 12.2 5.0 1.54 13 370.4
D979 8.3 7.5 0.8 12 604.8
D943 12.9 10 0.97 20 483.1
E059 7.8 15 0.83 23 632.9
E041 11.4 15 1.38 49 305.5
E039 11.1 15 1.04 31 471.7
D942 19.4 17.5 1.34 57 305.4
E042 11.4 17.5 1.12 32 541.8
E040 12.4 17.5 0.93 41 419.7
D983 11 20 1.09 48 409.0
E285 9.3 20 2.46 86 232.6
E286 10.4 20 2.55 100 198.8
E426 10 20 1.84 79 251.2
E455 14.2 20 2 73 270.6
*Dog E959 received 5 mg/kg/day on four consecutive days for a total of
20 mg/kg; by necessity, pharmacokinetic studies for the 5 mg/kg dose could be
determined only for 24 hours after the initial dose.
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count of ,103/mL and marrow cellularity of ,5% of nor-
mal were the criteria used for myeloablation.
Tr a n s p l a n t a t i o n
Four dogs had their autologous marrow aspirated under
general anesthesia and cry o p re s e rved as described [24].
Dogs were allowed to recover for 10–14 days after the mar-
row harvest, were treated with busulfan (20 mg/kg intra-
venously), and had the thawed marrow infused intravenously
30 hours after completion of the busulfan infusion. The
dose of mononuclear cells administered was 3.3–5.13108/kg
(median 4.53108/kg).
S u p p o rt i v e care
Dogs were maintained on oral fluid and food intake as
tolerated. Complete blood counts were obtained daily
beginning with the day of busulfan administration and con-
tinued until hematopoietic re c o v e ry or death with aplasia.
No seizure prophylaxis was given. When the absolute neu-
t rophil count (ANC) declined to ,131 09/L, dogs were
s t a rted on oral nonabsorbable and systemic antibiotics as
described [24]. Dogs were checked and weighed daily, and
the findings were recorded in individual records.
All dogs that died spontaneously or were killed had
complete autopsies (including marrow examination) per-
formed as described [24].
RESULTS
Dose escalation and my e l o s u p p re s s i o n
F i g u re 1 summarizes hematologic results of the dose
escalation study. Dogs experienced a busulfan dose–depen-
dent decline in peripheral blood cell counts. At doses of
3.75–15 mg/kg, all dogs re c o v e red hematopoietic function
and survived. One of three dogs given 17.5 mg/kg and both
dogs given 20 mg/kg (including the dog given four incre-
ments of 5 mg/kg) died with marrow aplasia.
White blood cell (WBC) count
With increasing doses of busulfan there was a progres-
sively steeper decline in WBC, with pro g ressively lower
nadirs reached between days 15 and 18 after busulfan injec-
tion. Even at the highest dose of busulfan (20 mg/kg), the
WBC nadir did not fall below 131 03/mL; remaining cells
were exclusively lymphocytes and monocytes.
N e u t ro p h i l s
The decline in neutrophils in general paralleled that in
WBC. However, the higher the busulfan dose, the earlier
the nadir was reached (day 18 for 5 mg/kg; day 13 for 20
mg/kg). At a dose of 20 mg/kg busulfan, the mean neu-
trophil count declined to ,10/mL.
P l a t e l e t s
Similarly, the platelet nadir (reached at 16–33 days) was
busulfan dose–dependent, although the kinetics of recovery
were somewhat obscured due to platelet transfusion support
given to prevent hemorrhage. At busulfan doses of 15–20
mg/kg, the platelet nadirs were below 103/mL.
On the basis of these findings (and the seizure - re l a t e d
death at a dose of 40 mg/kg) 20 mg/kg was considered the
marrow-ablative dose that was not associated with clinically
apparent non-marrow toxicity.
Hematopoietic r e s c u e
Four dogs (E285, E286, E426, E455) were given 20
mg/kg busulfan intravenously and, after a 30-hour interv a l ,
w e re infused with previously cry o p re s e rved autologous mar-
ro w. All four survived. Results are illustrated in Figure 2.
The nadirs for WBC, neutrophils, and platelets were less
p rofound than in dogs not given marrow rescue, due to the
beginning of reconstitution by infused marrow cells. Decline
and re c o v e ry of WBC and neutrophils were quite homoge-
neous for all four dogs, while in one dog (E286), platelet
re c o v e ry was somewhat protracted ($1 05/mL on day 37).
Figure 1. Peripheral blood cell counts in dogs given intravenous busulfan at doses of 3.75–20 mg/kg and no marrow rescue
Shown are the mean values of granulocytes (A) and platelets (B) by day after busulfan injections in four groups of dogs. Group 1 (m) includes dogs E180 (3.75
mg), D979 (7.5 mg), and D943 (10 mg); group 2 (H ) includes dogs E039, E041, and E059 (each given 15 mg/kg); group 3 (d) includes dogs D942, E040,
and E042 (each given 17.5 mg/kg); group 4 (j) includes dogs D959 and D983 (each given 20 mg/kg).
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Busulfan pharmacokinetics
P h a rmacokinetic results in the 15 evaluable dogs are
summarized in Table 1. After doses of 3.75–20 mg/kg, peak
plasma levels of 7279 to 25,582 ng/mL were measured. The
AUC ranged from 12 to 100 mg · h/mL. Elimination half-
lives were 0.8–2.55 hours. The t1/2 increased with the dose
of busulfan given. The AUC also increased, as expected,
with increasing busulfan doses. However, there was no tight
c o rrelation with AUC for a given dose level, with values
varying by as much as 106% (Table 1). Variations in plasma
clearance were even bro a d e r, ranging from 191.3 to 632.9
mL/hour (331%), and it is mostly on this basis that the
AUCs varied. These data show, therefore, that variability in
plasma levels is related not only to diff e rences in bioavail-
ability (after oral administration) but also to diff e rences in
drug elimination [13,27].
Toxicity and autopsy findings
The tolerability of intravenous busulfan administration
at doses of 3.75 to 20 mg/kg was excellent. One dog given
40 mg/kg died with neurotoxicity (convulsion). The major
toxicity was, as intended, marrow suppression with relative
sparing of lymphocytes. In dogs E059 and E040, given 15
and 17.5 mg/kg of busulfan, re s p e c t i v e l y, liver sections at
autopsy showed focal congestion and subendothelial edema
of central veins which, in E040, was associated with mild
hepatocyte destruction in zone 3 and replacement of degen-
erative hepatocytes by dilated sinusoids resembling peliosis.
In dog D983, given 20 mg/kg of busulfan and killed on day
25, the thymus failed to show clear cort i c o / m e d u l l a ry dis-
tinction. All dogs that died with marrow aplasia showed
intestinal mucosal hemorrhage.
DISCUSSION
Busulfan, a stem cell–toxic alkylating agent, is used
extensively to condition patients for autologous and allo-
geneic HSCT [1–4,8,10,20]. Currently, the standard admin-
istration of busulfan is in the form of an oral pre p a r a t i o n ,
and major intra- and interpatient fluctuations in bioavail-
ability have been re p o rted [11,12]. In children, generally
lower plasma levels than in adults are achieved after the oral
administration of identical per-kilogram busulfan doses
[10–13,27]. Furt h e rm o re, nausea and vomiting associated
with oral busulfan tend to interfere with timely administra-
tion of the prescribed doses. Clinical toxicity appears to cor-
relate with busulfan plasma levels [9,10,15], and re c e n t
results indicate that sustained engraftment of donor cells
and, at least in patients with chronic myelogenous leukemia,
p revention of disease re c u rrence after transplantation
depend on achieving effective drug plasma levels [2,10].
In an attempt to assure more consistent bioavailability,
busulfan preparations for intravenous administration have
been developed [12,19–23]. While several of these studies
used PEG-containing solutions, we dissolved busulfan in
DMSO and normal saline as used previously in pharmacoki-
netic studies in a canine model [19]. In the present study, we
used the same model to define a marrow-ablative dose of
intravenous busulfan and test the ability of autologous mar-
row cells to rescue dogs given myeloablative doses of intra-
venous busulfan.
A busulfan dose of 20 mg/kg, given either as a single
intravenous infusion or in increments of 5 mg/kg/day for
four consecutive days, consistently resulted in marrow abla-
tion with severe neutropenia and thrombocytopenia; there
was only a slight decrease in lymphocyte counts, quite simi-
lar to earlier observations in dogs treated with dimethyl-
busulfan [28]. Nonhematologic toxicity was minimal at
busulfan doses of 3.75–20 mg/kg and was limited to minor
histologic alterations in the liver. Neurotoxicity in the form
of convulsion and death in a dog given 40 mg/kg busulfan
intravenously was not unexpected, considering the well-
established effect of busulfan on the seizure threshold [7].
Pharmacokinetic data following intravenous administra-
tion of busulfan were more complex than anticipated. It
appeared that at the highest dose level studied (20 mg/kg),
Figure 2. Peripheral blood cell counts in four dogs
Dogs E285, E286, E426, and E455 were given 20 mg/kg busulfan followed 30 hours later by the infusion of autologous marrow cells. Data shown represent val-
ues in individual dogs. 
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plasma half-life may have been increased. Such a phenome-
non might be related to saturation of a distribution or elimi-
nation process. The AUC increased pro g ressively with the
dose of busulfan administered. For any given dose level,
however, there was considerable variation between individ-
ual animals. In the dose range where comparable data on
human patients are available, AUCs in dogs were somewhat
lower than would have been expected in humans, consistent
with a higher clearance in dogs [19]. To achieve AUCs com-
parable to those obtained in humans, 2.5- to 4-fold higher
busulfan doses were required in dogs. Extrapolation of the
canine data to patients suggests that intravenous doses up to
4–5 mg/kg will be safe even if given as a bolus. Single oral
doses of 4 mg/kg have been administered to patients with-
out undue toxicity [27]. If the intravenous preparation is
given over 2–4 hours rather than as a bolus, a plasma con-
centration profile similar to that obtained with oral dosing is
expected. Such a prolonged infusion would also be associat-
ed with a lower peak level and, presumably, would be well
tolerated. The present data show that, in addition to differ-
ences in absorption and bioavailability, important diff e r-
ences exist in the metabolism and elimination of busulfan
dependent on the route of administration. It is likely, there-
fore, that even with intravenous administration of busulfan,
monitoring of plasma levels and dose adjustment will be
required to consistently reach a desired target concentration
[11,13,15,16]. Nevertheless, these results may serve as a
guide for the clinical use of intravenous busulfan, in regard
to both dose requirements and dosing schedules.
Hematopoietic reconstitution in four dogs given autolo-
gous marrow infusions 30 hours after busulfan administra-
tion was uneventful, an indication that the drug was cleared
and the homing mechanism of hematopoietic stem cells and
m a rrow micro e n v i ronment were intact. The present study
was not designed to distinguish (for example, by gene mark-
ing) between re c o v e ry of hematopoiesis from infused vs.
residual endogenous cells. However, the kinetics of granulo-
cyte and platelet recovery clearly indicated that infused cells
were essential to recovery. In comparison to dogs that were
not rescued by marrow infusion, the blood cell nadirs
reached were higher, due to beginning repopulation fro m
the infused cells, and recovery was comparable to that seen
in dogs rescued after dimethylbusulfan [28] or lethal doses
of total-body irradiation [24,29]. 
The experiments described here did not investigate the
i m m u n o s u p p ressive effects of intravenous busulfan. Similar-
l y, it remains to be determined whether the present appro a c h
has the same antileukemic activity as the oral administration
of busulfan. However, the fact that marrow ablation was
achievable with a single intravenous dose is of interest and
might render such an approach attractive. For example, cry-
o p re s e rvation of autologous marrow would not be necessary,
since cells can easily be stored in the refrigerator for the
re q u i red time interval. Whether it would be preferable to use
other vehicles for the intravenous busulfan that provide dif-
f e rent drug stabilities remains to be determined [21–23].
Thus, observations in this large animal model show that
an intravenous preparation of DMSO-busulfan can be
a d m i n i s t e red safely at doses sufficient to achieve marro w
ablation. Hematopoietic reconstitution with autologous
transplanted marrow cells is prompt and complete. Howev-
er, while intravenous administration of busulfan circumvents
p roblems associated with variable absorption after oral
administration, it does not prevent individual variability
related to drug elimination and other processes.
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